# Palmitoyl Tripeptide-1 Peptide

> Palmitoyl Tripeptide-1 is a topical lipopeptide that supports fibroblast signaling, collagen activity, skin texture, and fine-line appearance.

Canonical: https://pepflow.app/peptides/palmitoyl-tripeptide-1/

The Collagen Messenger

A palmitoylated GHK-related cosmetic signal peptide used topically for skin-aging and texture claims, best understood as a matrikine-style collagen-support ingredient rather than a copper peptide or injectable drug.

Skin texture  Wrinkle appearance

Tier C

Evidence Emerging

Safety Limited Data

FDA status Not Approved

Topical 503A Not Listed

Last reviewed August 11, 2026 13 citations [How to read these labels](<https://pepflow.app/peptide-label-legend/>)

## What is Palmitoyl Tripeptide-1?

Palmitoyl Tripeptide-1 is a lipopeptide made by linking palmitic acid to the GHK tripeptide sequence, Gly-His-Lys. The palmitoyl group makes the molecule more lipid-friendly for topical cosmetic delivery than the bare tripeptide.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/39963574/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/34451799/>)

The GHK motif connects it conceptually to GHK-Cu, but Pal-GHK is not a copper complex. Its cosmetic rationale is matrikine-style signaling: collagen-fragment-like peptides can act as messages that encourage fibroblast activity and extracellular-matrix support in skin.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/39963574/>) [\[2\]](<https://pmc.ncbi.nlm.nih.gov/articles/PMC11946782/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/23467476/>)

In finished skincare, Palmitoyl Tripeptide-1 often appears in peptide blends, including formulas that pair it with Palmitoyl Tetrapeptide-7. That matters because combination-product results cannot automatically be attributed to Pal-GHK alone.[\[2\]](<https://pmc.ncbi.nlm.nih.gov/articles/PMC11946782/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/34451799/>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/39963574/>)

The clean positioning is topical cosmetic support for visible skin texture, fine lines, and firmness. It is not a wound-healing drug, not an injectable peptide protocol, and not interchangeable with GHK-Cu.[\[6\]](<https://www.fda.gov/cosmetics/cosmetics-laws-regulations/fda-authority-over-cosmetics-how-cosmetics-are-not-fda-approved-are-fda-regulated>) [\[7\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Palmitoyl%20Tripeptide-1%22&limit=1>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/39963574/>)

## What Palmitoyl Tripeptide-1 is investigated for

Palmitoyl Tripeptide-1 evidence is grouped by practical use case and topical route context. Each use case separates confidence, human evidence, animal or mechanistic support, and the practical takeaway.

### ### Collagen and elastin support Topical 50% Emerging

Collagen and elastin support is most defensible for finished formulas that include Palmitoyl Tripeptide-1; isolated ingredient efficacy needs stronger clinical data.[\[13\]](<https://pubmed.ncbi.nlm.nih.gov/38932444/>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/39963574/>)

#### Human evidence

A 12-week human eye-cream study used a multi-component active complex that included palmityl/palmitoyl tripeptide-1 and reported collagen-density and elasticity improvements. The result is formula-level evidence, not isolated Pal-GHK proof.[\[13\]](<https://pubmed.ncbi.nlm.nih.gov/38932444/>)

#### Animal / mechanistic evidence

GHK-related reviews describe Pal-GHK as a signal-peptide ingredient connected with collagen and extracellular-matrix support, while noting limited published ingredient-specific data.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/39963574/>) [\[2\]](<https://pmc.ncbi.nlm.nih.gov/articles/PMC11946782/>)

### ### Wrinkle appearance and firmness Topical 50% Emerging

Wrinkle appearance and firmness are reasonable cosmetic endpoints for finished formulas containing Pal-GHK, with ingredient-only claims kept below formula-level evidence.[\[13\]](<https://pubmed.ncbi.nlm.nih.gov/38932444/>) [\[6\]](<https://www.fda.gov/cosmetics/cosmetics-laws-regulations/fda-authority-over-cosmetics-how-cosmetics-are-not-fda-approved-are-fda-regulated>)

#### Human evidence

The same multi-component eye-cream study assessed photographs, hydration, elasticity, and dermatologist and participant ratings over 12 weeks, but the formula contained multiple active ingredients.[\[13\]](<https://pubmed.ncbi.nlm.nih.gov/38932444/>)

#### Animal / mechanistic evidence

Cosmeceutical peptide reviews place Pal-GHK and related lipopeptides in anti-wrinkle signal-peptide formulas, with formulation and skin penetration as practical constraints.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/39963574/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/34451799/>)

### ### Sensitive-skin retinoid alternative Topical 45% Preliminary

Palmitoyl Tripeptide-1 may fit sensitive-skin anti-aging routines as a non-retinoid peptide, but it has not been shown to replace retinoids or match retinoid outcomes.[\[3\]](<https://pubmed.ncbi.nlm.nih.gov/34451799/>) [\[6\]](<https://www.fda.gov/cosmetics/cosmetics-laws-regulations/fda-authority-over-cosmetics-how-cosmetics-are-not-fda-approved-are-fda-regulated>)

#### Human evidence

Sensitive-skin cosmetic reviews include peptide products but emphasize that volunteer data are limited and often not randomized placebo-controlled studies.[\[3\]](<https://pubmed.ncbi.nlm.nih.gov/34451799/>)

#### Animal / mechanistic evidence

Palmitoyl Tripeptide-1 is a non-retinoid signal peptide with matrix-support rationale, making it relevant to routines seeking cosmetic anti-aging support without retinoid-style positioning.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/39963574/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/23467476/>)

## Evidence snapshot

### Overall confidence

Emerging

52%

The strongest case is topical cosmetic plausibility, not drug-level proof. Pal-GHK has a coherent GHK-related signal-peptide rationale, but independent ingredient-only human outcome evidence is limited.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/39963574/>) [\[2\]](<https://pmc.ncbi.nlm.nih.gov/articles/PMC11946782/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/34451799/>)

Overall confidence is a page-level composite, not an average; it weighs evidence quality, route/molecule match, and practical limitations.

40%

### Human evidence

Preliminary

Human cosmetic evidence is often product- or blend-level, making it hard to isolate Palmitoyl Tripeptide-1 as the active driver.[\[2\]](<https://pmc.ncbi.nlm.nih.gov/articles/PMC11946782/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/34451799/>) [\[5\]](<https://clinicaltrials.gov/search?term=Palmitoyl%20Tripeptide-1>)

18%

### Animal / preclinical

Insufficient

Non-human support is indirect and mostly review-level. Pal-GHK is discussed as a GHK-related signal peptide in cosmetic collagen and matrix-support literature, but an independent animal or cell dossier for isolated Palmitoyl Tripeptide-1 was not identified.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/39963574/>) [\[2\]](<https://pmc.ncbi.nlm.nih.gov/articles/PMC11946782/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/34451799/>)

50%

### Mechanism support

Preliminary

GHK-related matrix signaling is plausible, but skin penetration and formulation can decide whether the ingredient reaches target cells at useful exposure.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/39963574/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/34451799/>)

## Forms & administration

Palmitoyl Tripeptide-1 is used in leave-on topical cosmetic products such as serums, creams, and peptide blends. It should not be treated as an injectable or systemic peptide protocol.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/39963574/>) [\[2\]](<https://pmc.ncbi.nlm.nih.gov/articles/PMC11946782/>) [\[6\]](<https://www.fda.gov/cosmetics/cosmetics-laws-regulations/fda-authority-over-cosmetics-how-cosmetics-are-not-fda-approved-are-fda-regulated>)

Topical

## Dosing & protocols

These ranges are general reference points, not personal dosing instructions.

### Typical Range

Topical amounts depend on the finished product.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/39963574/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/34451799/>)

### Frequency

Usually applied once or twice daily.[\[2\]](<https://pmc.ncbi.nlm.nih.gov/articles/PMC11946782/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/34451799/>)

### Timing Considerations

Apply in the morning or evening, following the normal skin-care routine.[\[4\]](<https://pubmed.ncbi.nlm.nih.gov/23467476/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/34451799/>)

### Cycle Length

Assess results after 8-12 weeks of consistent use.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/39963574/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/23467476/>)

[Full Palmitoyl Tripeptide-1 dosage guide](<https://pepflow.app/peptides/palmitoyl-tripeptide-1/dosage/>)

## What to expect

### First week

Smoother skin, better hydration, and less tightness as the topical routine starts.[\[4\]](<https://pubmed.ncbi.nlm.nih.gov/23467476/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/34451799/>)

### Weeks 4-8

Modest cosmetic change: smoother texture, softer-looking fine lines, and better hydrated-looking skin as the routine stays consistent.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/39963574/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/23467476/>)

### Weeks 8-12

Small before-and-after difference in texture, fine-line appearance, or overall skin smoothness.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/39963574/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/34451799/>)

### After stopping

Quick fade in hydration and surface-smoothness benefits when the formula is stopped, with deeper cosmetic effects softening gradually through normal skin turnover and changes in the rest of the routine.[\[4\]](<https://pubmed.ncbi.nlm.nih.gov/23467476/>)

## Safety profile

Safety should be treated as topical cosmetic tolerability. The practical concerns are irritation, sensitivity, damaged-skin use, product formulation, and avoiding injection or therapeutic claims.[\[3\]](<https://pubmed.ncbi.nlm.nih.gov/34451799/>) [\[6\]](<https://www.fda.gov/cosmetics/cosmetics-laws-regulations/fda-authority-over-cosmetics-how-cosmetics-are-not-fda-approved-are-fda-regulated>)

### Common side effects

- Redness [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/34451799/>)
- Stinging or burning [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/34451799/>)
- Breakouts or rash [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/34451799/>)

### Cautions

- Damaged or inflamed skin[\[6\]](<https://www.fda.gov/cosmetics/cosmetics-laws-regulations/fda-authority-over-cosmetics-how-cosmetics-are-not-fda-approved-are-fda-regulated>)
- Not injectable[\[6\]](<https://www.fda.gov/cosmetics/cosmetics-laws-regulations/fda-authority-over-cosmetics-how-cosmetics-are-not-fda-approved-are-fda-regulated>) [\[7\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Palmitoyl%20Tripeptide-1%22&limit=1>)

### What we don't know

Independent ingredient-only efficacy, long-term use beyond typical cosmetic windows, pregnancy safety, and formulation-specific penetration remain the main unknowns.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/39963574/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/34451799/>) [\[5\]](<https://clinicaltrials.gov/search?term=Palmitoyl%20Tripeptide-1>)

## Who Palmitoyl Tripeptide-1 is not for

Route-specific avoid and medical-review notes:

- **Broken, irritated, or inflamed skin**

  Wait for barrier recovery or get medical guidance before applying cosmetic peptide products to broken, infected, severely irritated, or recently treated skin.[\[6\]](<https://www.fda.gov/cosmetics/cosmetics-laws-regulations/fda-authority-over-cosmetics-how-cosmetics-are-not-fda-approved-are-fda-regulated>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/34451799/>)
- **Known cosmetic ingredient sensitivity**

  Prior reactions to peptides, preservatives, fragrances, solvents, or other blend ingredients should guide patch testing and product selection.[\[3\]](<https://pubmed.ncbi.nlm.nih.gov/34451799/>)
- **Pregnancy, breastfeeding, or pediatric use**

  Dedicated Pal-GHK safety data are not established for pregnancy, breastfeeding, or pediatric anti-aging use.[\[3\]](<https://pubmed.ncbi.nlm.nih.gov/34451799/>)

## Drug & supplement interactions

Documented interactions are separated from theoretical or route-specific cautions.

### Theoretical interactions

- **Retinoids, acids, and strong actives**

  Layering Pal-GHK with retinoids, exfoliating acids, benzoyl peroxide, or low-pH vitamin C can increase irritation or make attribution unclear.[\[4\]](<https://pubmed.ncbi.nlm.nih.gov/23467476/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/34451799/>)
- **Other peptide blends**

  Using several peptide blends at once makes it harder to know which ingredient is helping or irritating the skin.[\[2\]](<https://pmc.ncbi.nlm.nih.gov/articles/PMC11946782/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/34451799/>)

## Regulatory status

### United States

United States: no FDA-approved Palmitoyl Tripeptide-1 or Palmitoyl Oligopeptide drug product was identified in the reviewed openFDA query. Topical cosmetic use is separate from therapeutic claims, and cosmetics are regulated but generally not FDA-premarket-approved except color additives.[\[7\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Palmitoyl%20Tripeptide-1%22&limit=1>) [\[6\]](<https://www.fda.gov/cosmetics/cosmetics-laws-regulations/fda-authority-over-cosmetics-how-cosmetics-are-not-fda-approved-are-fda-regulated>)

| Route | FDA drug approval | 503A compounding |
| --- | --- | --- |
| Topical | Not Approved · openFDA Drugs@FDA queries for Palmitoyl Tripeptide-1 and Palmitoyl Oligopeptide returned no matching approved drug product. Cosmetic appearance products are regulated separately from therapeutic drug claims.[\[7\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Palmitoyl%20Tripeptide-1%22&limit=1>) [\[6\]](<https://www.fda.gov/cosmetics/cosmetics-laws-regulations/fda-authority-over-cosmetics-how-cosmetics-are-not-fda-approved-are-fda-regulated>) | Not Listed · The current 503A bulk-substances PDF review did not identify Palmitoyl Tripeptide-1 or Palmitoyl Oligopeptide as a listed nominated substance. That does not convert cosmetic ingredient use into drug approval.[\[8\]](<https://www.fda.gov/media/94155/download>) |

### Topical

FDA drug approval

Not Approved

openFDA Drugs@FDA queries for Palmitoyl Tripeptide-1 and Palmitoyl Oligopeptide returned no matching approved drug product. Cosmetic appearance products are regulated separately from therapeutic drug claims.[\[7\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Palmitoyl%20Tripeptide-1%22&limit=1>) [\[6\]](<https://www.fda.gov/cosmetics/cosmetics-laws-regulations/fda-authority-over-cosmetics-how-cosmetics-are-not-fda-approved-are-fda-regulated>)

503A compounding

Not Listed

The current 503A bulk-substances PDF review did not identify Palmitoyl Tripeptide-1 or Palmitoyl Oligopeptide as a listed nominated substance. That does not convert cosmetic ingredient use into drug approval.[\[8\]](<https://www.fda.gov/media/94155/download>)

### International

International status is product-, market-, and claim-specific. EU/Europe, the UK, Canada, and Australia regulate cosmetic products through cosmetic or industrial-chemical frameworks, while therapeutic claims may trigger drug or medicine rules.[\[9\]](<https://eur-lex.europa.eu/eli/reg/2009/1223/oj/eng>) [\[10\]](<https://www.gov.uk/guidance/making-cosmetic-products-available-to-consumers-in-great-britain>) [\[11\]](<https://www.canada.ca/en/health-canada/services/consumer-product-safety/cosmetics/regulatory-information.html>) [\[12\]](<https://www.industrialchemicals.gov.au/cosmetics-and-soap>)

### Sports & competition

Topical cosmetic Palmitoyl Tripeptide-1 has no specific anti-doping issue identified in the reviewed materials. Injectable or systemic use is not athlete-cleared because it is not an approved drug route.[\[7\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Palmitoyl%20Tripeptide-1%22&limit=1>)

## How it works

The mechanism starts with GHK, a small peptide motif associated with matrix-remodeling and repair biology. Palmitoyl Tripeptide-1 keeps that motif but changes the delivery profile by adding a fatty acid tail.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/39963574/>)

The palmitoyl group is meant to help a topical peptide interact with the lipid-rich skin barrier. That does not guarantee delivery to fibroblasts; it makes formulation quality central to interpretation.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/39963574/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/34451799/>)

Pal-GHK is not GHK-Cu. Without the copper complex, the emphasis is topical cosmetic signaling rather than copper-dependent GHK-Cu biology.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/39963574/>)

## Research gaps & open questions

What the current literature has not yet settled about Palmitoyl Tripeptide-1:

01

Ingredient-only human trials need to show how much Palmitoyl Tripeptide-1 improves wrinkles or skin quality by itself, separate from other ingredients in a finished formula.[\[2\]](<https://pmc.ncbi.nlm.nih.gov/articles/PMC11946782/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/34451799/>)

02

Delivery studies should compare product base, pH, concentration, and blends to show how much peptide reaches living skin.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/39963574/>)

03

Direct comparisons should test whether adding Palmitoyl Tripeptide-1 improves results beyond retinoids, vitamin C, niacinamide, sunscreen, or cosmetic procedures.[\[4\]](<https://pubmed.ncbi.nlm.nih.gov/23467476/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/34451799/>)

04

Long-term and special-population safety are not well established for routine use of Palmitoyl Tripeptide-1 by itself.[\[3\]](<https://pubmed.ncbi.nlm.nih.gov/34451799/>)

## Common questions

### Is Palmitoyl Tripeptide-1 a copper peptide?

No. Pal-GHK is a palmitoylated GHK-related cosmetic peptide, not GHK-Cu or another copper complex.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/39963574/>)

### Is Palmitoyl Tripeptide-1 the same as Matrixyl 3000?

No. Palmitoyl Tripeptide-1 is one ingredient used in some Matrixyl-style blends; blend-level results should not automatically be credited to Pal-GHK alone.[\[2\]](<https://pmc.ncbi.nlm.nih.gov/articles/PMC11946782/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/34451799/>)

### How long does Palmitoyl Tripeptide-1 take to assess?

Use weeks rather than days. A fair check is around 8-12 weeks, looking for subtle changes in skin texture, fine-line appearance, and overall smoothness; if those do not change, the product may not be adding much beyond the rest of the routine.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/39963574/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/23467476/>)

### Can Palmitoyl Tripeptide-1 replace a retinoid?

It should be viewed as a cosmetic-support active, not a retinoid replacement. Retinoids and peptides work through different evidence bases and tolerability profiles.[\[4\]](<https://pubmed.ncbi.nlm.nih.gov/23467476/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/34451799/>)

### Can Palmitoyl Tripeptide-1 be injected?

No. The supporting evidence is for topical cosmetic use; cosmetic Pal-GHK products are not sterile injectable medicines.[\[6\]](<https://www.fda.gov/cosmetics/cosmetics-laws-regulations/fda-authority-over-cosmetics-how-cosmetics-are-not-fda-approved-are-fda-regulated>) [\[7\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Palmitoyl%20Tripeptide-1%22&limit=1>)

## Myths & misconceptions

### Myth

Pal-GHK and GHK-Cu are interchangeable.

### Reality

They share the GHK motif, but Pal-GHK is palmitoylated for topical cosmetic delivery while GHK-Cu is a copper complex with different biology and evidence.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/39963574/>)

### Myth

If a peptide blend works, Palmitoyl Tripeptide-1 alone must be responsible.

### Reality

Finished products often combine multiple peptides and actives. Ingredient-only attribution requires evidence that separates Pal-GHK from the rest of the formula.[\[2\]](<https://pmc.ncbi.nlm.nih.gov/articles/PMC11946782/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/34451799/>)

### Myth

Topical cosmetic peptides can be injected for stronger results.

### Reality

Cosmetic Pal-GHK preparations are not injectable drugs and have no reviewed injectable safety or efficacy basis.[\[6\]](<https://www.fda.gov/cosmetics/cosmetics-laws-regulations/fda-authority-over-cosmetics-how-cosmetics-are-not-fda-approved-are-fda-regulated>) [\[7\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Palmitoyl%20Tripeptide-1%22&limit=1>)

## History & discovery

Palmitoyl Tripeptide-1 developed as part of the cosmetic-peptide movement around matrikine and signal-peptide ingredients. Its most familiar market position is topical anti-aging skincare, often inside peptide blends.[\[2\]](<https://pmc.ncbi.nlm.nih.gov/articles/PMC11946782/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/34451799/>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/39963574/>)

Palmitoylated signal peptides became common in anti-aging formulas, with Palmitoyl Tripeptide-1 frequently discussed in blend and ingredient literature.[\[2\]](<https://pmc.ncbi.nlm.nih.gov/articles/PMC11946782/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/34451799/>)

A GHK topical review discussed GHK-Cu and Pal-GHK use in anti-wrinkle products while emphasizing insufficient published information on permeability, effectiveness, and physicochemical properties.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/39963574/>)

## Published research 13 citations

- [\[1\] **Topically applied GHK as an anti-wrinkle peptide: Advantages, problems and prospective.** PubMed / BioImpacts, 2025. review.](<https://pubmed.ncbi.nlm.nih.gov/39963574/>)
- [\[2\] **Current Approaches in Cosmeceuticals: Peptides, Biotics and Marine Biopolymers.** PMC / Pharmaceutics, 2025. review.](<https://pmc.ncbi.nlm.nih.gov/articles/PMC11946782/>)
- [\[3\] **Usage of Synthetic Peptides in Cosmetics for Sensitive Skin.** PubMed / Pharmaceuticals, 2021-07-21. review.](<https://pubmed.ncbi.nlm.nih.gov/34451799/>)
- [\[4\] **Skin anti-aging strategies.** PubMed / Dermato-Endocrinology, 2012-07-01. review.](<https://pubmed.ncbi.nlm.nih.gov/23467476/>)
- [\[5\] **ClinicalTrials.gov query for Palmitoyl Tripeptide-1 and Palmitoyl Oligopeptide** ClinicalTrials.gov. clinical trial registry.](<https://clinicaltrials.gov/search?term=Palmitoyl%20Tripeptide-1>)
- [\[6\] **FDA Authority Over Cosmetics: How Cosmetics Are Not FDA-Approved, but Are FDA-Regulated** U.S. Food and Drug Administration, 2025-11-20. official guidance.](<https://www.fda.gov/cosmetics/cosmetics-laws-regulations/fda-authority-over-cosmetics-how-cosmetics-are-not-fda-approved-are-fda-regulated>)
- [\[7\] **openFDA Drugs@FDA query for Palmitoyl Tripeptide-1 and Palmitoyl Oligopeptide** openFDA / U.S. Food and Drug Administration. database query.](<https://api.fda.gov/drug/drugsfda.json?search=%22Palmitoyl%20Tripeptide-1%22&limit=1>)
- [\[8\] **Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act** U.S. Food and Drug Administration, 2026-05-14. regulatory.](<https://www.fda.gov/media/94155/download>)
- [\[9\] **Regulation (EC) No 1223/2009 of the European Parliament and of the Council on cosmetic products** EUR-Lex. official guidance.](<https://eur-lex.europa.eu/eli/reg/2009/1223/oj/eng>)
- [\[10\] **Making cosmetic products available to consumers in Great Britain** UK Office for Product Safety and Standards. official guidance.](<https://www.gov.uk/guidance/making-cosmetic-products-available-to-consumers-in-great-britain>)
- [\[11\] **Cosmetics regulatory information** Health Canada. official guidance.](<https://www.canada.ca/en/health-canada/services/consumer-product-safety/cosmetics/regulatory-information.html>)
- [\[12\] **Cosmetics and soap** Australian Industrial Chemicals Introduction Scheme. official guidance.](<https://www.industrialchemicals.gov.au/cosmetics-and-soap>)
- [\[13\] **Comprehensive evaluation of the efficacy and safety of a new multi-component anti-aging topical eye cream.** PubMed / Skin Research and Technology, 2024. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/38932444/>)

[PepFlow library coverage](<https://pepflow.app/research/peptide-library/>)

## Quick facts

**Family**

Matrikine/copper tripeptide

**Tier**

C

**Evidence**

52% Emerging

**Safety**

Limited Data

**FDA status**

Not Approved

**Topical 503A**

Not Listed

**Citations**

[13 citations](<https://pepflow.app/peptides/palmitoyl-tripeptide-1/#published-research>)

**Updated**

August 11, 2026

### Potential benefits

- Collagen and elastin support
- Wrinkle appearance and firmness
- Sensitive-skin retinoid alternative

### Common side effects

- Redness
- Stinging or burning
- Breakouts or rash

### Also known as

- Pal-GHK
- Palmitoyl-GHK
- Palmitoyl oligopeptide
- Biopeptide CL

## Related

- [Peptide Label Key](<https://pepflow.app/peptide-label-legend/>)
- [Palmitoyl Tripeptide-1 dosage guide](<https://pepflow.app/peptides/palmitoyl-tripeptide-1/dosage/>)
- [PepFlow Library Statistics (2026) · 65 Profiles](<https://pepflow.app/research/peptide-library/>)
